Latest Balance Sheet News

Evolution Mining has approved nearly $800 million in capital investments across key projects, aiming to boost production and returns significantly. The company also expands its exploration footprint in Canada, signaling a robust growth strategy.

Evolution Mining has reported a record-breaking first half of FY26 with statutory net profit soaring 110% to $767 million and a fully franked interim dividend of 20 cents per share. Strong operational discipline and favourable metal prices underpin this robust performance.

Evolution Mining has reported a record half-year profit, with statutory net income more than doubling to $766.6 million, driven by higher gold and copper prices. The company also declared a fully franked interim dividend of 20 cents per share and progressed key mine expansions and developments.

Centuria Industrial REIT has reported a strong first half for 2025, with total revenue surging over 20% and net profit rising by 10%, while distributions remain steady.

AGL Energy reported a steady half-year performance with flat EBITDA and a slight dip in net profit, underpinned by improved operational metrics and strategic moves including a major telco divestment and renewable investments.

Evolution Energy Minerals Limited has announced a renounceable pro-rata entitlement offer to raise up to $4.03 million, aiming to fund exploration and development of its Tanzanian copper and graphite assets. The offer includes free attaching options and is partially underwritten, reflecting both opportunity and risk amid regulatory challenges.

Pantera Minerals has completed its inaugural modern geochemical sampling program at the Gilham Silver-Antimony Project in Arkansas, uncovering new geological insights and setting the stage for drilling. The company maintains a disciplined capital approach amid rising silver prices.

AGL Energy reported a steady first half with flat underlying EBITDA and a narrowed FY26 earnings outlook, while accelerating its renewable projects and forming a strategic partnership with Aussie Broadband.

Argenica Therapeutics has reported a significant increase in its half-year loss to $3.82 million, driven by reduced revenue and higher research and development expenses. The company continues to invest heavily in its neuroprotective drug candidate ARG-007 amid ongoing clinical trials.

CSL Limited has released its half-year results showing a slight revenue decline amid ongoing transformation efforts, while maintaining its full-year guidance and expanding its share buyback program.

CSL Limited reported a 7% decline in underlying NPATA to US$1.9 billion for the half-year, weighed down by restructuring costs and impairments, yet maintains full-year guidance and expands its share buy-back program.

CSL Limited reported a sharp 80% drop in net profit for the half year ended December 2025, driven by significant restructuring and impairment charges, yet maintained its growth guidance and dividend payout.